Federal regulators ordered the embattled Emergent BioSolutions plant in Baltimore to stop producing new Johnson & Johnson vaccine material pending a completed inspection, the company said Monday. 

In a regulatory filing with the Securities and Exchanges Commission released Monday, Emergent said it "agreed not to initiate the manufacturing of any new material" for Johnson & Johnson's vaccine "and to quarantine existing material" until the Food and Drug Administration (FDA) finishes its inspection.

The FDA began its inspection April 12, the company said.

 Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more

Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens

"While we await the FDA’s full feedback, we are working with J&J and the FDA on strengthening the supply chain for this vitally important vaccine," Emergent said in an e-mailed statement to The Hill.

"We recognize the confusion these recent events may have caused our customers, our employees, and the public. We are steadfastly committed to full compliance with the FDA’s strict requirements. We acknowledge that there are improvements we must make to meet the high standards we have set for ourselves and to restore confidence in our quality systems and manufacturing processes," the company said.

The disclosure from Emergent is the latest blow to Johnson & Johnson's ramping up of domestic production for its coronavirus vaccine. Read more at The Hill